论文部分内容阅读
目的观察低分子肝素钙(博璞青天津红日药业股份有限公司)治疗不稳定型心绞痛(UA)的临床疗效。方法将52例UA患者随机分两组:治疗组26例,在常规口服阿斯匹林(100mg/d)及抗心绞痛药物基础上加用皮下注射低分子肝素钙(4100IU bid连续7天);对照组26例,仅常规口服阿斯匹林及抗心绞痛药物。结果1周后总有效率:治疗组为96.15%,对照组61.54%(P<0.05);观察4周治疗组无一例发生急性心肌梗死,对照组则发生2例,同时治疗组亦未发现有明显的不良反应。结论UA患者在常规治疗基础上加用博璞青,能更有效地控制心绞痛发作,减少心肌梗死发生率,同时也安全便利。
Objective To observe the clinical effect of low molecular weight heparin calcium (Bo Pu Qing Tian Hong Ri Pharmaceutical Co., Ltd.) in the treatment of unstable angina pectoris (UA). Methods A total of 52 patients with UA were randomly divided into two groups: the treatment group (26 cases), subcutaneous injection of low molecular weight heparin (4100 IU bid for 7 consecutive days) on the basis of routine oral aspirin (100 mg / d) and antianginal drugs; Control group of 26 patients, only routine oral aspirin and anti-angina drugs. Results After 1 week, the total effective rate was 96.15% in the treatment group and 61.54% in the control group (P <0.05). No acute myocardial infarction was observed in the 4-week treatment group, 2 cases in the control group and no concurrent treatment group Obvious adverse reactions. Conclusion UA patients in the conventional treatment based on the use of Bo Pu Qing, can more effectively control angina pectoris, reduce the incidence of myocardial infarction, but also safe and convenient.